In December 2025, the World Ovarian Cancer Coalition convened patients, clinicians, researchers, and policy leaders to examine global access to biomarker testing in ovarian cancer.
Biomarker-informed care, including BRCA and HRD testing, is transforming treatment. Yet major inequities persist. Women in many regions lack access to timely testing and targeted therapies, while awareness gaps remain even in high-income countries.
This report captures key insights and practical recommendations to advance equitable, precision care worldwide.
Read and download the Full Report here.
Key Findings
Uneven Access
Significant disparities exist in testing availability, affordability, and infrastructure, particularly in low- and middle-income countries.
Awareness Gaps
Limited clinician and patient awareness continues to hinder uptake.
Delays in Results
Timely access to test results is critical for treatment decision-making.
Need for Standardised Pathways
Clear guidelines and sustainable funding models are essential to scale equitable access.
Calls to Action
This report outlines practical steps to ensure biomarker testing benefits all women.
We encourage stakeholders to:
- Strengthen clinician education and awareness around biomarker testing
- Advocate for standardised, timely testing pathways
- Promote patient-friendly communication and informed decision-making
- Support sustainable funding models to expand equitable access
- Use the findings to strengthen your advocacy and policy engagement
By aligning policy, education, and access, we can bring biomarker-informed ovarian cancer care to every woman, everywhere.
For questions, inquiries, or to get involved, contact mikis@worldovariancancercoalition.org